Switch theme
Sign up to access all valuation multiples
Ever Supreme Bio Technology Co Ltd is a Taiwan-based company. The company is engaged in research, development, and manufacturing of new drugs related to human mesenchymal stem cells and immune cells. The company operates in two segments: Cell Preparation Business Unit and Other Operating Business. The company gained a majority of revenue from the cell preparation Business, which is engaged in the research, development, manufacture, and sales of various new drugs and cell preparations, and investments related to biotechnology and medical industry businesses.
2016
99
LTM Revenue $34.1M
LTM EBITDA $16.6M
$429M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ever Supreme Bio Technology has a last 12-month revenue (LTM) of $34.1M and a last 12-month EBITDA of $16.6M.
In the most recent fiscal year, Ever Supreme Bio Technology achieved revenue of $31.1M and an EBITDA of $16.4M.
Ever Supreme Bio Technology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ever Supreme Bio Technology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $34.1M | XXX | $31.1M | XXX | XXX | XXX |
| Gross Profit | $23.6M | XXX | $22.0M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $16.6M | XXX | $16.4M | XXX | XXX | XXX |
| EBITDA Margin | 49% | XXX | 53% | XXX | XXX | XXX |
| EBIT | $15.2M | XXX | $15.5M | XXX | XXX | XXX |
| EBIT Margin | 45% | XXX | 50% | XXX | XXX | XXX |
| Net Profit | $13.1M | XXX | $12.2M | XXX | XXX | XXX |
| Net Margin | 38% | XXX | 39% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ever Supreme Bio Technology's stock price is TWD 171 (or $6).
Ever Supreme Bio Technology has current market cap of TWD 13.6B (or $454M), and EV of TWD 12.9B (or $429M).
See Ever Supreme Bio Technology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $429M | $454M | XXX | XXX | XXX | XXX | $0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ever Supreme Bio Technology has market cap of $454M and EV of $429M.
Ever Supreme Bio Technology's trades at 13.8x EV/Revenue multiple, and 26.1x EV/EBITDA.
Equity research analysts estimate Ever Supreme Bio Technology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ever Supreme Bio Technology has a P/E ratio of 34.6x.
See valuation multiples for Ever Supreme Bio Technology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $454M | XXX | $454M | XXX | XXX | XXX |
| EV (current) | $429M | XXX | $429M | XXX | XXX | XXX |
| EV/Revenue | 12.6x | XXX | 13.8x | XXX | XXX | XXX |
| EV/EBITDA | 25.9x | XXX | 26.1x | XXX | XXX | XXX |
| EV/EBIT | 28.2x | XXX | 27.6x | XXX | XXX | XXX |
| EV/Gross Profit | 18.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 34.6x | XXX | 37.1x | XXX | XXX | XXX |
| EV/FCF | 29.7x | XXX | 29.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEver Supreme Bio Technology's last 12 month revenue growth is 17%
Ever Supreme Bio Technology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Ever Supreme Bio Technology's rule of 40 is 103% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ever Supreme Bio Technology's rule of X is 90% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ever Supreme Bio Technology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 49% | XXX | 53% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | -8% | XXX | XXX | XXX |
| Rule of 40 | 103% | XXX | 69% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 90% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ever Supreme Bio Technology acquired XXX companies to date.
Last acquisition by Ever Supreme Bio Technology was XXXXXXXX, XXXXX XXXXX XXXXXX . Ever Supreme Bio Technology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ever Supreme Bio Technology founded? | Ever Supreme Bio Technology was founded in 2016. |
| Where is Ever Supreme Bio Technology headquartered? | Ever Supreme Bio Technology is headquartered in Taiwan. |
| How many employees does Ever Supreme Bio Technology have? | As of today, Ever Supreme Bio Technology has 99 employees. |
| Is Ever Supreme Bio Technology publicy listed? | Yes, Ever Supreme Bio Technology is a public company listed on ROCO. |
| What is the stock symbol of Ever Supreme Bio Technology? | Ever Supreme Bio Technology trades under 6712 ticker. |
| When did Ever Supreme Bio Technology go public? | Ever Supreme Bio Technology went public in 2018. |
| Who are competitors of Ever Supreme Bio Technology? | Similar companies to Ever Supreme Bio Technology include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's current market cap is $454M |
| What is the current revenue of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's last 12 months revenue is $34.1M. |
| What is the current revenue growth of Ever Supreme Bio Technology? | Ever Supreme Bio Technology revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Ever Supreme Bio Technology? | Current revenue multiple of Ever Supreme Bio Technology is 12.6x. |
| Is Ever Supreme Bio Technology profitable? | Yes, Ever Supreme Bio Technology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's last 12 months EBITDA is $16.6M. |
| What is Ever Supreme Bio Technology's EBITDA margin? | Ever Supreme Bio Technology's last 12 months EBITDA margin is 49%. |
| What is the current EV/EBITDA multiple of Ever Supreme Bio Technology? | Current EBITDA multiple of Ever Supreme Bio Technology is 25.9x. |
| What is the current FCF of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's last 12 months FCF is $14.4M. |
| What is Ever Supreme Bio Technology's FCF margin? | Ever Supreme Bio Technology's last 12 months FCF margin is 42%. |
| What is the current EV/FCF multiple of Ever Supreme Bio Technology? | Current FCF multiple of Ever Supreme Bio Technology is 29.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
